CLH Shares Rise 10.4% in 6 Months: Here's What You Should Know

Clean Harbors raised 2026 adjusted EBITDA guidance by $110 million at the midpoint to $1.38 billion, with a $1.35-$1.41 billion range, and lifted adjusted free-cash-flow guidance to $520-$580 million. PFAS-related revenue exceeded $120 million in 2025 and was tracking above 30% year-over-year growth in Q2 2026, while Q3 adjusted EBITDA is expected to rise 24-28%. Operating cash flow increased 15% year over year to $239 million in Q2, supporting repurchases and a remaining authorization of nearly $550 million.

Analysis

CLH’s incremental earnings quality hinges on whether PFAS becomes a recurring regulated-remediation annuity rather than episodic project revenue. Its integrated treatment chain creates switching costs and capacity scarcity, which should support price realization as municipal and industrial compliance deadlines approach; smaller hazardous-waste operators lack the permitting and thermal-destruction footprint to replicate this quickly. The more material second-order beneficiary is the re-refining business: sustained industrial activity raises collection volumes and utilization, allowing fixed-cost absorption to compound margins independently of remediation demand.

Near-term, the raised outlook creates a favorable estimate-revision setup into Q3, but the emergency-response component is inherently volatile and should not receive the same valuation multiple as contracted PFAS work. The market may also be underestimating execution risk from permitting, community opposition to incineration, and evolving standards around destruction versus containment of PFAS. A sequential slowdown in PFAS bookings, lower re-refined-product spreads, or Q3 EBITDA growth below the guided range would challenge the premium-growth thesis within 1-3 months.

The contrarian view is that CLH is not necessarily the cleanest PFAS expression after an extended relative move: regulatory demand can be real while revenue conversion remains constrained by public procurement cycles and treatment-capacity approvals. VLTO offers a lower-beta adjacent exposure through water-quality measurement and treatment infrastructure, but lacks CLH’s direct remediation operating leverage. The appropriate structural thesis is a 6-18 month capacity-and-compliance trade, not a one-quarter extrapolation of emergency activity.

Key Decisions for Investors

• Initiate a 1-3 month tactical long CLH only on post-results weakness or confirmation that Q3 EBITDA is tracking within/above guidance; target 10-15% upside from estimate revisions and buyback support, with a 7% stop or exit if PFAS growth falls below 25% year-over-year.
• Use a 6-12 month pair: long CLH / short a diversified environmental-services proxy such as WCN, sized beta-neutral. Thesis: CLH’s scarce hazardous-waste and PFAS treatment capacity should outgrow conventional solid-waste volumes; close if CLH’s EBITDA margin fails to expand year-over-year for two consecutive quarters.
• Add VLTO as a lower-volatility satellite rather than a substitute for CLH, ahead of municipal water-capex awards over the next 6-18 months. Maintain smaller sizing because direct PFAS revenue sensitivity is less transparent; reassess following order growth and margin guidance.
• Set a diligence alert for disclosed PFAS backlog, contract duration, and destruction-versus-disposal mix at the next CLH report. Without those data, do not underwrite the PFAS opportunity as recurring revenue or pay a further multiple premium.